Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 18 Show results per page	View Search Criteria \| Help With Results

Last Modified: 7/23/2008 First Published: 8/3/2007


1.		Phase III Randomized Study of the Effects of Dietary Soy on Estrogens in Breast Fluid, Serum, and Urine Samples From Healthy Women

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Biomarker/Laboratory analysis, Prevention				Active				30 to 45				NCI				UHM-CHS-4116 CHS 14116, NCT00513916

Last Modified: 8/27/2008 First Published: 3/24/2004


2.		Phase II Pilot Chemoprevention Study of Deslorelin in Combination With Low-Dose Add-Back Estradiol and Testosterone in Premenopausal Women With or Without a BRCA Gene Mutation Who Are at High Risk for Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				21 to 48				NCI				CHNMC-IRB-02164 NCT00080756

Last Modified: 1/5/2009 First Published: 5/28/2004


3.		Phase II Study of Exemestane in Postmenopausal Women at High Risk for Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				Postmenopausal				NCI				GUMC-2007-313 NCI-04-C-0044, NCT00085072, GUMC-2007-313, GT 07-313, 2007-313

Last Modified: 10/11/2007 First Published: 8/24/2004


4.		Phase II Randomized Pilot Study of Letrozole in Postmenopausal Women at Increased Risk For Breast Cancer Based on Elevated Estradiol Levels

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				35 and over				NCI				DFCI-00024 UCLA-0210012-02, NCT00090857


5.		Soy Isoflavones and Breast Cancer Risk Reduction

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				30 to 42				NCI, Other				03-260 UTMB GCRC #635, NIH R01-CA95545, NIH NCRR GCRC M01 RR00073, NCT00204490

Last Modified: 6/2/2006 First Published: 5/23/2006


6.		Phase II Chemoprevention Study of Simvastatin in Women at High Risk of Developing a New Breast Cancer After Undergoing Surgical Resection for Ductal Carcinoma in Situ or Stage I-III Invasive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention				Active				18 and over				NCI				JHOC-J0485 JHOC-SKCCC-J0485, JHOC-04100404, NCT00334542

Last Modified: 8/13/2007 First Published: 7/14/2006


7.		Phase II Pilot Study of Simvastatin on the Pharmacokinetics of Anastrozole in Postmenopausal Women With History of Invasive Breast Cancer or Ductal Carcinoma In Situ or At High Risk for Developing Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Biomarker/Laboratory analysis, Prevention, Treatment				Active				Postmenopausal				NCI				JHOC-J05100 JHOC-SKCCC-J05100, NCT00354640


8.		Study of Breast Cancer Prevention by Letrozole in High Risk Women

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Prevention				Active				30 to 69				NCI, Other				10587 NCT00579826

Last Modified: 11/2/2007 First Published: 12/22/2004


9.		Phase I Pilot Chemoprevention Study of IH636 Grape Seed Proanthocyanidin Extract in Healthy Postmenopausal Women at High Risk of Developing Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Prevention				Active				40 to 75				NCI				CHNMC-IRB-03178 NCT00100893

Last Modified: 4/10/2008 First Published: 8/10/2007


10.		Phase I Randomized Study of Green Tea Catechin Extract (Polyphenon E) in Women With a History of Hormone Receptor-Negative Stage I-III Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Biomarker/Laboratory analysis, Prevention, Treatment				Active				21 to 65				NCI				MDA-MDA04-4-01 MDA04-4-01, NCT00516243, MDA-2006-0521, CPMC-IRB-AAAB7638

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute